Subscribe to RSS
DOI: 10.1055/s-2005-870525
Bone Microenvironment-related Growth Factors, Zoledronic Acid and Dexamethasone Differentially Modulate PTHrP Expression in PC-3 Prostate Cancer Cells
Publication History
Received 4 January 2005
Accepted after revision 25 April 2005
Publication Date:
08 November 2005 (online)
Abstract
Bone metastasis microenvironment-related growth factors such as insulin-like growth factor 1 (IGF-1), transforming growth factor beta 1 (TGF-β1), basic fibroblast growth factor (bFGF) and interleukin 6 (IL-6) show survival factor activity, thereby inhibiting chemotherapy-induced apoptosis of PC-3 prostate cancer cells in vitro. Recently, zoledronic acid has been shown to induce apoptosis in PC-3 prostate cancer cells while overexpression of parathyroid hormone-related protein (PTHrP) inhibits serum deprivation-induced apoptosis in PC-3 cells. Consequently, we have investigated whether IGF-1, TGF-β1, bFGF, IL-6, zoledronic acid and/or dexamethasone affect the expression of the PTHrP and type I PTH/PTHrP receptor (PTH.1R) in PC-3 prostate cancer cells using relative quantitative PCR and real-time PCR (expression at mRNA level) and immunocytochemical and immunofluorescence analysis (expression at protein level). Our data show that IGF-1, TGF-β1, bFGF and IL-6 increase PTHrP mRNA expression and its perinuclear localization, while zoledronic acid (50 μM, 100 μM for 24 h and 48 h) and dexamethasone suppress PTHrP expression in PC-3 cells. We did not detect any appreciable change of the PTH.1R expression due to IGF-1, TGF- β1, bFGF, IL-6, zoledronic acid or dexamethasone in PC-3 cells. Therefore, it is conceivable that bone metastasis microenvironment-related survival factor/anti-apoptotic activity and zoledronic acid anticancer action/pro-apoptotic activity on PC-3 cells is mediated, at least in part, by differential modulation of PTHrP expression.
Key words
PTHrP - PC-3 cell - Bone-derived growth factors - Zoledronic acid
References
- 1 Suva L J, Winslow G A, Wettenhall R E, Hammonds R G, Moseley J M, Diefenbach-Jagger H, Rodda C P, Kemp B E, Rodriguez H, Chen E Y. et al . A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science. 1987; 237 893-896
- 2 Chirgwin J M, Guise T A. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr. 2000; 10 159-178
- 3 Ikeda K, Weir E C, Mangin M, Dannies P S, Kinder B, Deftos L J, Brown E M, Broadus A E. Expression of messenger ribonucleic acids encoding a parathyroid hormone-like peptide in normal human and animal tissues with abnormal expression in human parathyroid adenomas. Mol Endocrinol. 1988; 2 1230-1236
- 4 Amizuka N, Warshawsky H, Henderson J E, Goltzman D, Karaplis A C. Parathyroid hormone-related peptide-depleted mice show abnormal epiphyseal cartilage development and altered endochondral bone formation. J Cell Biol. 1994; 126 1611-1623
- 5 Qian J, Colbert M C, Witte D, Kuan C Y, Gruenstein E, Osinska H, Lanske B, Kronenberg H M, Clemens T L. Midgestational lethality in mice lacking the parathyroid hormone (PTH)/PTH-related peptide receptor is associated with abrupt cardiomyocyte death. Endocrinology. 2003; 144 1053-1061
- 6 Tovar Sepulveda V A, Falzon M. Parathyroid hormone-related protein enhances PC-3 prostate cancer cell growth via both autocrine/paracrine and intracrine pathways. Regul Pept. 2002; 105 109-120
- 7 Tovar Sepulveda V A, Shen X, Falzon M. Intracrine PTHrP protects against serum starvation-induced apoptosis and regulates the cell cycle in MCF-7 breast cancer cells. Endocrinology. 2002; 143 596-606
- 8 Koutsilieris M, Mitsiades C, Sourla A. Insulin-like growth factor I and urokinase-type plasminogen activator bioregulation system as a survival mechanism of prostate cancer cells in osteoblastic metastases: development of anti-survival factor therapy for hormone-refractory prostate cancer. Mol Med. 2000; 6 251-267
- 9 Deftos L J. Prostate carcinoma: production of bioactive factors. Cancer. 2000; 88 (12 Suppl) 3002-3008
- 10 Sugihara A, Maeda O, Tsuji M, Tsujimura T, Nakata Y, Akedo H, Kotake T, Terada N. Expression of cytokines enhancing the osteoclast activity, and parathyroid hormone-related protein in prostatic cancers before and after endocrine therapy: an immunohistochemical study. Oncol Rep. 1998; 5 1389-1394
- 11 Cheville J C, Tindall D, Boelter C, Jenkins R, Lohse C M, Pankratz V S, Sebo T J, Davis B, Blute M L. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival. Cancer. 2002; 95 1028-1036
- 12 Koivisto P, Kolmer M, Visakorpi T, Kallioniemi O P. Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol. 1998; 152 1-9
- 13 Keller E T, Zhang J, Cooper C R, Smith P C, McCauley L K, Pienta K J, Taichman R S. Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev. 2001; 20 333-349
- 14 Zayzafoon M, Abdulkadir S A, McDonald J M. Notch signaling and ERK activation are important for the osteomimetic properties of prostate cancer bone metastatic cell lines. J Biol Chem. 2004; 279 3662-3670
- 15 Reyes-Moreno C, Sourla A, Choki I, Doillon C, Koutsilieris M. Osteoblast-derived survival factors protect PC-3 human prostate cancer cells from adriamycin apoptosis. Urology. 1998; 52 341-347
- 16 Koutsilieris M, Tzanela M, Dimopoulos T. Novel concept of antisurvival factor (ASF) therapy produces an objective clinical response in four patients with hormone-refractory prostate cancer: case report. Prostate. 1999; 38 313-316
- 17 Koutsilieris M, Mitsiades C, Dimopoulos T, Ioannidis A, Ntounis A, Lambou T. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients. J Clin Endocrinol Metab. 2001; 86 5729-5736
- 18 Koutsilieris M, Mitsiades C, Dimopoulos T, Vacalicos J, Lambou T, Tsintavis A, Milathianakis C, Bogdanos J, Karamanolakis D. Combination of dexamethasone and a somatostatin analogue in the treatment of advanced prostate cancer. Expert Opin Investig Drugs. 2002; 11 283-293
- 19 Hsieh C L, Kubo H, Chung L W. Gene therapy for prostate cancer bone metastasis. Gene therapy targeting bone metastasis. Cancer Treat Res. 2004; 118 231-290
- 20 Dimopoulos M A, Kiamouris C, Gika D, Deliveliotis C, Giannopoulos A, Zervas A, Alamanis C, Constantinidis C, Koutsilieris M. Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study. Urology. 2004; 63 120-125
- 21 Mundy G R, Yoneda T. Bisphosphonates as anticancer drugs. N Engl J Med. 1998; 339 398-400
- 22 Lee Y P, Schwarz E M, Davies M, Jo M, Gates J, Zhang X, Wu J, Lieberman J R. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model. Cancer Res. 2002; 62 5564-5570
- 23 Saad F, Gleason D M, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin J L, Vinholes J J, Goas J A, Chen B. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94 1458-1468
- 24 Saad F, Gleason D M, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin J L, Vinholes J J, Goas J A, Zheng M. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004; 96 879-882
- 25 Saad F, Schulman C C. Role of bisphosphonates in prostate cancer. Eur Urol. 2004; 45 26-34
- 26 Dumon J C, Journe F, Kheddoumi N, Lagneaux L, Body J J. Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells. Eur Urol. 2004; 45 521-528; discussion 528 - 529
- 27 Lee M V, Fong E M, Singer F R, Guenette R S. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. 2001; 61 2602-2608
- 28 Papapoulos S E, Hamdy N A, van der Pluijm G. Bisphosphonates in the management of prostate carcinoma metastatic to the skeleton. Cancer. 2000; 88 (Suppl) 3047-3053
- 29 Kaighn M E, Narayan K S, Ohnuki Y, Lechner J F, Jones L W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol. 1979; 17 16-23
- 30 Borner M M, Myers C E, Sartor O, Sei Y, Toko T, Trepel J B, Schneider E. Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3. Cancer Res. 1995; 55 2122-2128
- 31 Pergolizzi R G, Kreis W, Rottach C, Susin M, Broome J D. Mutational status of codons 12 and 13 of the N- and K-ras genes in tissue and cell lines derived from primary and metastatic prostate carcinomas. Cancer Invest. 1993; 11 25-32
- 32 Iwamura M, Abrahamsson P A, Foss K A, Wu G, Cockett A T, Deftos L J. Parathyroid hormone-related protein: a potential autocrine growth regulator in human prostate cancer cell lines. Urology. 1994; 43 675-679
- 33 Dougherty K M, Blomme E A, Koh A J, Henderson J E, Pienta K J, Rosol T J, McCauley L K. Parathyroid hormone-related protein as a growth regulator of prostate carcinoma. Cancer Res. 1999; 59 6015-6022
- 34 Tenta R, Tiblalexi D, Sotiriou E, Lembessis P, Manoussakis M, Koutsilieris M. Bone microenvironment-related growth factors modulate differentially the anticancer actions of zoledronic acid and doxorubicin on PC-3 prostate cancer cells. Prostate. 2004; 59 120-131
- 35 Wu G, Iwamura M, di Sant’Agnese P A, Deftos L J, Cockett A T, Gershagen S. Characterization of the cell-specific expression of parathyroid hormone-related protein in normal and neoplastic prostate tissue. Urology. 1998; 51 (Suppl) 110-120
- 36 Wojcik S F, Capen C C, Rosol T J. Expression of PTHrP and the PTH/PTHrP receptor in purified alveolar epithelial cells, myoepithelial cells, and stromal fibroblasts derived from the lactating rat mammary gland. Exp Cell Res. 1999; 248 415-422
- 37 Urwin G H, Percival R C, Harris S, Beneton M N, Williams J L, Kanis J A. Generalised increase in bone resorption in carcinoma of the prostate. Br J Urol. 1985; 57 721-723
- 38 Mitsiades C S, Koutsilieris M. Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer. Expert Opin Investig Drugs. 2001; 10 1099-1115
- 39 Mundy G R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002; 2 584-593
- 40 Dimitriadou V, Koutsilieris M. Mast cell-tumor cell interactions: for or against tumour growth and metastasis?. Anticancer Res. 1997; 17 1541-1549
- 41 Bogdanos J, Karamanolakis D, Tenta R, Tsintavis A, Milathianakis C, Mitsiades C, Koutsilieris M. Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton. Endocr Relat Cancer. 2003; 10 279-289
- 42 Karamanolakis D, Bogdanos J, Sourla A, Milathianakis C, Tsintavis A, Lembessis P, Tenta R, Tiblalexi D, Koutsilieris M. Molecular evidence-based use of bone resorption-targeted therapy in prostate cancer patients at high risk for bone involvement. Mol Med. 2002; 8 667-675
- 43 Koutsilieris M, Reyes-Moreno C, Sourla A, Dimitriadou V, Choki I. Growth factors mediate glucocorticoid receptor function and dexamethasone-induced regression of osteoblastic lesions in hormone refractory prostate cancer. Anticancer Res. 1997; 17 1461-1465
- 44 Pizzi H, Gladu J, Carpio L, Miao D, Goltzman D, Rabbani S A. Androgen regulation of parathyroid hormone-related peptide production in human prostate cancer cells. Endocrinology. 2003; 144 858-867
- 45 Blomme E A, Dougherty K M, Pienta K J, Capen C C, Rosol T J, McCauley L K. Skeletal metastasis of prostate adenocarcinoma in rats: morphometric analysis and role of parathyroid hormone-related protein. Prostate. 1999; 39 187-197
- 46 Hullinger T G, McCauley L K, DeJoode M L, Somerman M J. Effect of bone proteins on human prostate cancer cell lines in vitro. Prostate. 1998; 36 14-22
- 47 Lam M H, Thomas R J, Martin T J, Gillespie M T, Jans D A. Nuclear and nucleolar localization of parathyroid hormone-related protein. Immunol Cell Biol. 2000; 78 395-402
- 48 Jans D A, Thomas R J, Gillespie M T. Parathyroid hormone-related protein (PTHrP): a nucleocytoplasmic shuttling protein with distinct paracrine and intracrine roles. Vitam Horm. 2003; 66 345-384
- 49 Guise T A. Parathyroid hormone-related protein and bone metastases. Cancer. 1997; 80 (Suppl) 1572-1580
- 50 Reyes-Moreno C, Frenette G, Boulanger J, Lavergne E, Govindan M V, Koutsilieris M. Mediation of glucocorticoid receptor function by transforming growth factor beta I expression in human PC-3 prostate cancer cells. Prostate. 1995; 26 260-269
Michael Koutsilieris, M. D., Ph. D
Department of Experimental Physiology
Medical School · University of Athens · 75 Micras Asias · Goudi · Athens 115 27 · Greece
Phone: +30 (210) 746 25 97 ·
Fax: +30 (210) 814 58 71
Email: mkouts@medscape.com